EMERGENCY AUTHORIZATION AND REGULATORY CONTROL OF IMMUNE THERAPIES DURING PANDEMICS

1. INTRODUCTION

Emergency authorization of immune therapies during pandemics refers to the temporary regulatory mechanisms through which governments permit the use of immunological treatments before completion of the ordinary drug approval process. Such therapies may include monoclonal antibodies, convalescent plasma, immunoglobulins, cytokine-targeting medicines, immune modulators, and other biological products intended to prevent or treat serious infectious diseases.

During pandemics, conventional clinical development and approval procedures may be too slow to address urgent public health needs. Emergency authorization therefore provides a mechanism for making potentially beneficial treatments available under exceptional circumstances.

However, emergency authorization does not eliminate requirements relating to scientific evidence, patient safety, informed consent, manufacturing quality, pharmacovigilance, and regulatory supervision. The central legal challenge is balancing rapid access to potentially life-saving treatments against the risk of ineffective, unsafe, or inadequately evaluated medical interventions.

2. INTERNATIONAL LEGAL AND REGULATORY FRAMEWORK

A. WORLD HEALTH ORGANIZATION FRAMEWORK

The World Health Organization (WHO) has established regulatory and ethical frameworks for evaluating medical products during public health emergencies.

Its Emergency Use Listing (EUL) procedure evaluates the quality, safety, and efficacy evidence available for products intended to address public health emergencies. EUL is a WHO assessment mechanism and is not itself a national marketing authorization.

B. INTERNATIONAL HEALTH REGULATIONS, 2005

The International Health Regulations establish international obligations concerning the prevention, detection, assessment, and response to public health emergencies of international concern.

Articles 12 and 13 address the determination of public health emergencies of international concern and public health response capacities. These provisions provide an international coordination framework but do not independently authorize individual medicines.

C. TRIPS AGREEMENT

The Agreement on Trade-Related Aspects of Intellectual Property Rights provides the international framework for pharmaceutical patent protection.

Article 31 permits compulsory licensing under specified conditions, including public non-commercial use and national emergencies, subject to applicable requirements. This mechanism can support access to essential immune therapies during pandemics.

D. INTERNATIONAL COVENANT ON ECONOMIC, SOCIAL AND CULTURAL RIGHTS

Article 12 recognises the right to the highest attainable standard of physical and mental health. It supports government responsibilities concerning access to essential medical treatment and public health protection.

3. LEGAL FRAMEWORK IN THE UNITED STATES AND EUROPEAN UNION

A. UNITED STATES: FDA EMERGENCY USE AUTHORIZATION

Section 564 of the Federal Food, Drug, and Cosmetic Act authorises the US Food and Drug Administration to issue Emergency Use Authorizations (EUAs) in qualifying circumstances.

The principal statutory requirements include:

A qualifying emergency declaration or determination.

Evidence that the product may be effective against the relevant disease.

A determination that known and potential benefits outweigh known and potential risks.

No adequate, approved, and available alternative, subject to the statutory standard.

Appropriate conditions governing distribution, administration, and information provided to healthcare professionals and patients.

An EUA is not equivalent to full FDA approval. It is an exceptional authorization subject to regulatory conditions and possible revision or termination.

B. EUROPEAN UNION: CONDITIONAL MARKETING AUTHORISATION

Regulation (EC) No. 507/2006 provides the framework for conditional marketing authorisation of medicinal products.

Conditional authorization may be granted where immediate availability offers a favourable benefit-risk balance, comprehensive clinical data are not yet available, and the applicant is expected to provide further evidence.

Regulation (EC) No. 726/2004 establishes the centralised EU authorisation framework, while Regulation (EU) 2022/123 strengthens the European Medicines Agency's role in crisis preparedness and management.

4. EMERGENCY AUTHORIZATION REQUIREMENTS FOR IMMUNE THERAPIES

A. SCIENTIFIC EVIDENCE

Regulators must examine available preclinical and clinical evidence, including the proposed therapeutic benefit, safety profile, manufacturing consistency, and limitations of the available data.

B. BENEFIT-RISK ASSESSMENT

The potential clinical benefits must be assessed against known and reasonably anticipated risks. Relevant considerations include adverse immune reactions, hypersensitivity, immune suppression, and other treatment-related complications.

C. MANUFACTURING QUALITY

Biological immune therapies must comply with applicable Good Manufacturing Practice requirements. Regulators should examine product identity, purity, potency, consistency, sterility, and batch-release controls.

D. INFORMED CONSENT

Patients should receive appropriate information about the therapy's emergency status, known risks, potential benefits, available alternatives, and remaining uncertainties.

E. PHARMACOVIGILANCE

Manufacturers and healthcare institutions must comply with applicable adverse-event reporting and safety-monitoring obligations. Regulators may impose additional monitoring, reporting, and follow-up conditions.

5. INDIAN LEGAL AND REGULATORY FRAMEWORK

In India, emergency authorization of immune therapies operates primarily through the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, and applicable regulatory directions.

The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services, plays a central role in regulating new drugs and biological products.

Important legal considerations include:

Drugs and Cosmetics Act, 1940: Establishes the statutory framework for regulating drugs and preventing the manufacture and distribution of substandard or unlawfully marketed products.

New Drugs and Clinical Trials Rules, 2019: Govern clinical trials, regulatory permissions, ethics committees, and specified new-drug requirements.

Drugs Rules, 1945: Provide additional requirements concerning drug manufacture, import, sale, and distribution.

Article 21 of the Constitution: Protects life and personal liberty and informs the state's responsibilities concerning healthcare and patient safety.

Article 14: Requires non-arbitrary and legally justifiable regulatory decision-making.

Emergency regulatory permission must be distinguished from ordinary marketing approval. The precise legal route depends on the product, its classification, available evidence, and applicable government directions.6. RELEVANT JUDICIAL DECISIONS AND CASE LAWS

A. JACOBSON v. MASSACHUSETTS (1905) – DIRECT AUTHORITY ON EMERGENCY PUBLIC HEALTH POWERS

The United States Supreme Court upheld the authority of Massachusetts to enforce compulsory vaccination measures under its public health legislation. The Court recognised that individual liberty may be subject to reasonable public health restrictions during infectious disease emergencies.

Legal significance: The judgment establishes that governments possess public health regulatory powers during epidemics, but such powers remain subject to constitutional limitations. It provides an important foundation for evaluating emergency immunological interventions.

B. FDA v. BROWN & WILLIAMSON TOBACCO CORP. (2000) – ANALOGOUS AUTHORITY ON REGULATORY JURISDICTION

The United States Supreme Court examined the statutory authority of the FDA and the limits of administrative interpretation under federal legislation.

Legal significance: The decision demonstrates that regulatory agencies must exercise powers within the authority granted by legislation. Emergency authorization of immune therapies must therefore have a valid statutory foundation.

C. ABIGAIL ALLIANCE FOR BETTER ACCESS TO DEVELOPMENTAL DRUGS v. VON ESCHENBACH (2007) – DIRECTLY RELEVANT TO EXPERIMENTAL TREATMENT ACCESS

The United States Court of Appeals for the District of Columbia Circuit considered whether terminally ill patients possess a constitutional right to access investigational drugs that have not completed the ordinary approval process.

The court rejected the claimed broad constitutional right to obtain experimental drugs outside the regulatory framework.

Legal significance: Emergency availability of immune therapies must operate through recognised regulatory mechanisms rather than an assumed constitutional entitlement to unapproved treatment.

D. JACOB PULIYEL v. UNION OF INDIA (2022) – INDIAN ANALOGOUS AUTHORITY

The Supreme Court of India considered challenges concerning COVID-19 vaccination policies, informed consent, vaccine safety information, and adverse-event reporting.

The Court emphasised the importance of transparency concerning vaccine-related adverse events and held that individuals should not be compelled to undergo vaccination without appropriate constitutional and legal justification.

Legal significance: The judgment is relevant to emergency immunological interventions because it highlights informed consent, medical transparency, and the importance of post-administration safety monitoring.

E. STATE OF PUNJAB v. MOHINDER SINGH CHAWLA (1997) – INDIAN DIRECT AUTHORITY ON MEDICAL TREATMENT RIGHTS

The Supreme Court of India recognised that the right to health is integral to the right to life under Article 21 of the Constitution.

Legal significance: The decision supports the state's responsibility to facilitate access to appropriate healthcare, including potentially essential treatments during public health emergencies, subject to applicable regulatory and clinical safeguards.

F. PARMANAND KATARA v. UNION OF INDIA (1989) – INDIAN DIRECT AUTHORITY ON EMERGENCY MEDICAL CARE

The Supreme Court held that preservation of human life is of paramount importance and that medical professionals have an obligation to provide necessary emergency assistance.

Legal significance: The judgment supports the principle that emergency medical response should not be obstructed by unnecessary procedural barriers. However, it does not remove statutory requirements governing the authorization of investigational medicines.

G. SELL v. UNITED STATES (2003) – ANALOGOUS AUTHORITY ON MEDICAL AUTONOMY

The United States Supreme Court considered the circumstances in which the government could administer antipsychotic medication involuntarily to a criminal defendant to restore competency to stand trial.

The Court established strict requirements concerning governmental interests, medical appropriateness, necessity, and less intrusive alternatives.

Legal significance: The judgment provides useful principles for evaluating involuntary administration of immune therapies, particularly where emergency treatment raises questions of bodily autonomy and medical consent.

7. LIABILITY AND REGULATORY ACCOUNTABILITY

Emergency authorization does not automatically eliminate legal responsibility for pharmaceutical manufacturers, healthcare institutions, or regulatory authorities.

A. MANUFACTURER LIABILITY

Manufacturers may face liability for defective products, misleading safety information, manufacturing failures, or breaches of applicable statutory obligations.

B. HEALTHCARE PROFESSIONAL LIABILITY

Medical practitioners must exercise appropriate professional judgment, obtain legally sufficient consent, and follow applicable clinical standards.

C. REGULATORY LIABILITY

Regulatory authorities must act within statutory powers, consider relevant scientific evidence, and provide legally defensible reasons for significant regulatory decisions.

D. COMPENSATION FOR ADVERSE EVENTS

Governments may establish compensation arrangements for vaccine or medicine-related injuries. However, eligibility, causation requirements, and compensation procedures depend on the relevant national legislation or specific emergency programme.

8. PRACTICAL COMPLIANCE REQUIREMENTS

Organisations seeking emergency authorization for immune therapies should:

Establish the applicable emergency regulatory pathway before distribution.

Submit available clinical and scientific evidence.

Demonstrate an acceptable benefit-risk assessment.

Maintain biological-product manufacturing quality standards.

Obtain appropriate ethics committee approvals for clinical research.

Provide transparent patient information and informed-consent documentation.

Establish adverse-event reporting and pharmacovigilance systems.

Maintain traceability of manufactured and distributed batches.

Comply with additional authorization conditions and reporting deadlines.

Submit further clinical evidence where required by regulators.

9. CONCLUSION

Emergency authorization of immune therapies during pandemics is an important component of modern public health regulation. It enables governments to respond rapidly to serious infectious disease threats while maintaining essential safeguards concerning efficacy, safety, manufacturing quality, informed consent, and accountability.

The United States, European Union, India, and international organisations employ different regulatory mechanisms to facilitate emergency access to medical products. Judicial decisions such as Jacobson v. Massachusetts, Abigail Alliance v. von Eschenbach, and Jacob Puliyel v. Union of India provide important principles concerning public health powers, experimental treatment access, patient autonomy, and regulatory accountability.

Ultimately, emergency authorization must remain evidence-based, proportionate, transparent, temporary where appropriate, and subject to continuing scientific and legal review. Public health urgency can justify accelerated regulatory procedures, but it cannot justify abandoning fundamental patient rights or statutory safety requirements.